Keep REMS ed optional: AAFP

Share this article:

At an FDA public meeting on issues and challenges around risk evaluation and mitigation strategy (REMS), the AAFP urged the agency to keep REMS-specific CME for extended-release and long-acting opioids voluntary, reported AAFP News Now.

Ann Karty, MD, medical director of the AAFP division of CME, said a prescriber-education mandate could impact patient access to those drugs.

It could also create confusion for doctors who are licensed in multiple states.

“If you start adding more requirements… there is the potential that some will not participate,” Karty told AAFP News Now.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters